Polaryx Therapeutics, Inc. (PLYX)
NCM · Healthcare · Biotechnology
$1.99
+0.00%
Closing price as of 2026-07-29 · Source: TEK2day Finance
Key Metrics
Market Cap
$99.2M
Shares Outstanding
49.8M
Exchange
NCM
Currency
USD
About Polaryx Therapeutics, Inc.
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -884K | -974K | -911K | -2.0M |
| Net Income | -1.0M | -1.4M | -1.5M | -2.5M |
| Diluted EPS | $-0.02 | $-0.03 | $nan | $-0.05 |
Annual Financials
| Metric | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 |
| Operating Income | -3.8M | -4.4M | -7.8M |
| Net Income | -3.8M | -30.4M | -9.0M |
| Diluted EPS | $-0.08 | $-0.64 | $nan |